iCare Finland, a subsidiary of Revenio Group, has completed the acquisition of the artificial intelligence (AI) software company Thirona Retina B.V.

iCare already distributes Thirona Retina’s leading RetCad product as part of its Illume retinal screening solution. RetCad screens fundus images for diseases, including diabetic retinopathy, agerelated macular degeneration, and glaucoma. With AI, it processes large amounts of data quickly, speeding up the screening process. Its clinical performance has been repeatedly validated by independent clinical studies.1,2

Jouni Toijala, CEO of Revenio Group, said the acquisition of Thirona Retina will strengthen the company’s ability to further develop AIbased ophthalmic solutions.

“We see that AI will increasingly be integrated into a wide range of products. With the addition of Thirona Retina, we are better positioned to develop other AI-based solutions for eye care to support clinical decision making. Thirona Retina will continue to sell RetCad artificial intelligence solution to other vendors in the industry. We will also continue our previous cooperations with other artificial intelligence providers.

"With the acquisition of Oculo in 2021, we gained a stateof-the-art software platform and a skilled team. With the help of Oculo’s cloud-based software platform and the team, we have developed a unique, comprehensive retinal screening solution that includes the fully automated and fast iCare DRSplus fundus imaging system, iCare Illume software platform, and RetCad AI,” said Mr Toijala.

References available at mivision.com.au.